Product information

COLYHOPE/COLYCRIT: Lyophilized powder for injection
Active Ingredient: COLISTIMETHATE SODIUM
Strength: 1,000,000 IU/ 2,000,000 IU/ 3,000,000 IU
Primary Pack: Vial for injection
Therapeutic Indication: Infections caused by Gram-negative bacteria, lung infection in patients with cystic fibrosis (CF).

What is Colistimethate Sodium?

Colistimethate sodium is indicated in the treatment of the following infections where sensitivity testing suggests that they are caused by susceptible bacteria.
• Intravenous administration for the treatment of some serious infections caused by Gram-negative
bacteria, including those of the lower respiratory tract and urinary tract, when more commonly
used systemic antibacterial agents may be contraindicated or may be ineffective because of
bacterial resistance.
• Treatment by inhalation of Pseudomonas aeruginosa lung infection in patients with cystic fibrosis (CF).

Why Colihope?

Globally there is a growing threat from the emergence of multidrug-resistant (MDR) microorganisms. Their increasing prevalence is causing major clinical problems in patients with burns, neutropenia, or cystic fibrosis, and in immunocompromised patients.

Colihope, our GMP and FDA approved antibiotic, promises to treat Pseudomonas aeruginosa infections in cystic fibrosis patients and other certain bacterial infections by stopping the growth of MDR bacteria.